bluebird bio Inc. will have an eventful 2020, including the submission of three different products for regulatory approvals, but at least one milestone will be reached a little later than previously expected.
The company launched its gene therapy Zynteglo (autologous CD34+ cells encoding βA-T87Q-globin gene) in the EU, where it was approved...